Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...
Laboratory experiments with human tonsil-derived fibroblasts show that senescent lymphoid stromal cells suppress B cell ...
A small longitudinal study of 12 transplant recipients found that two-dimensional B-cell receptor analysis revealed ...
Results from a Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer ...
Results from a phase I clinical trial led by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer ...
Identify cost-efficient trial locations, investment opportunities and enrollment trends to sharpen strategy and gain a competitive advantage.Dublin, Oct. (GLOBE NEWSWIRE) -- "Diffuse Large B-Cell ...
Advances in diffuse large B-cell lymphoma treatment may improve outcomes for people who are living with this type of cancer. Diffuse large B-cell lymphoma (DLBCL) is the most common type of ...
A phase I trial of OX40-enhanced CAR-T therapy showed remissions in several B-cell non-Hodgkin lymphomas, researchers ...
Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results